Log In

 

Company Name : Boehringer Ingelheim

Thursday, March 1, 2018 11:59PM IST (6:29PM GMT)

(BW)(BOEHRINGER-INGELHEIM)

Boehringer Ingelheim Starts New Campaign: ‘Why wait in IPF?’


Rare Disease Day draws attention to the importance of early diagnosis and treatment of IPF.; Even though international guidelines recommend to offer antifibrotic treatment to the majority of individuals with IPF, research in Europe shows that around 40% of patients with confirmed IPF do not receive antifibrotic treatment.1; Boehringer Ingelheim provides physicians with insights into progression of IPF as well as the benefits of early diagnosis and intervention.


Ingelheim, Germany

On Rare Disease Day, 28 February, Boehringer Ingelheim emphasises the question: ‘Why wait in IPF?´ while awareness activities are focussing on highlighting the benefits of early diagnosis and considering early treatment of idiopathic pulmonary fibrosis (IPF). IPF is a rare, debilitating and fatal lung disease which affects approximately 3 million people worldwide.2

 

Diagnosing IPF can be difficult because typically, patients with IPF present with nonspecific symptoms usually attributed to ageing, deconditioning or other comorbidities.2 The median time from first symptoms to diagnosis is around two years.3 Early and accurate diagnosis of IPF is important, as interventions such as antifibrotic therapies, supplemental oxygen treatment, cough management and pulmonary rehabilitation may help patients to better manage their condition.

 

In IPF a key concern is that many patients who are diagnosed with the disease remain untreated. In 2016, 290 respiratory physicians from five European countries participated in an online survey about IPF treatment in patients under their care. The survey showed that, of patients with a confirmed diagnosis, 40% did not receive treatment.1

 

IPF is unpredictable and damage is permanent.Without appropriate medical intervention the opportunity to slow disease progression is lost. “Slowing disease progression and preserving lung function by reducing decline should be the primary goal for all physicians when treating individuals with IPF. For this reason, initiation of treatment at diagnosis is vital”, commented Professor Toby Maher, Royal Brompton Hospital, UK.

 

While a cure for IPF has not been found yet, two approved antifibrotic drugs shown to slow disease progression in IPF are recommended for the majority of patients by international guidelines.4 At the time of diagnosis, IPF patients should feel empowered to take an active approach to managing their disease by learning all they can about it, and discussing with their treating physicians what treatment options and approaches are available.

 

New resources released for Rare Disease Day can be found at Boehringer-Ingelheim.com.

 

More information on IPF for physicians can be found at inIPF. Further information for patients can be found at Life with IPF.

 

~ ENDS ~

 

Please click on the link below for ‘Notes to Editors’ and ‘References’:

 

https://www.boehringer-ingelheim.com/press-release/IPFwhywait

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com


More News from Boehringer Ingelheim

17/09/2018 1:19PM

Large European real-world study reports effects of Spiolto® Respimat® for people living with COPD in daily clinical practice1

OTIVACTO study reported improvements in both physical functioning and general condition in people living with COPD receiving Spiolto® (tiotropium/olodaterol) Respimat® therapy1 4 out of 5 ...

17/09/2018 9:15AM

Clinical trial data for nintedanib in patients with advanced IPF published

INSTAGE® trial results published in the New England Journal of Medicine1 Trial provides clinical data on patients with IPF and severe impairment in gas exchange usually excluded from clinical trials1 Efficacy ...

17/09/2018 9:00AM

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

INPULSIS®-ON study indicates safety and efficacy of Ofev® (nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS® trials1 Results from INPULSIS®-ON, the ...

Similar News

25/09/2018 7:05PM

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC

– ALTA-1L Met its Primary Endpoint Showing Superiority in Blinded Independent Review Committee-Assessed Progression-Free Survival Compared to Crizotinib – – Data Will Be Presented During the ...

No Image

25/09/2018 4:00PM

WIPO and IFPMA Launch New Online Patent-Search Resource to Help Health Agencies Procure Medicines

WIPO and the research-based pharmaceutical industry today launched a new online tool designed to help procurement agencies better understand the global patent status of medicines.   This press release features ...